In a recent announcement on her social media account, President Claudia Sheinbaum detailed the signing of an agreement involving the Secretaría de Salud, Birmex, Liomont, and Moderna. The primary goal of this agreement is to enhance the production capabilities of vaccines within Mexico, which is critical in the ongoing efforts to combat health crises such as COVID-19.

Sheinbaum highlighted that Birmex, Liomont, and Moderna are the key players that previously contributed to the manufacturing of COVID-19 vaccines. This move is seen as a strategic measure to not only bolster the country’s vaccine supply but also to potentially strengthen Mexico's position in biopharmaceutical manufacturing. The implications of this agreement could lead to greater self-sufficiency in vaccine production, reducing reliance on international suppliers.

The article concludes by emphasizing that this is a developing story. Milenio encourages its readers to stay connected through their platforms for the latest updates, reflecting the significance of the announcement as it unfolds. This agreement comes at a time when countries are increasingly recognizing the importance of local vaccine production in ensuring public health security.